Commentary|Videos|February 26, 2026

RB-1355 Shows Safety in Lymphoma Trials

Fact checked by: Paige Britt

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, explained the adverse events associated with RB-1355 and how they compare to other lymphoma treatments.


Latest CME